Before taking Retevmo(Selpercatinib)

The administration of RETEVMO requires vigilant monitoring for several potentially serious toxicities, including effects on the liver, lungs, cardiovascular system, and wound healing, necessitating proactive management strategies.

Critical Warnings and Precautionary Measures for RETEVMO Therapy

RETEVMO therapy mandates careful consideration of several warnings. Hepatotoxicity is a significant concern, requiring liver function monitoring (ALT/AST) before and during treatment, with dose adjustments for elevations. Interstitial Lung Disease (ILD)/Pneumonitis, potentially severe or fatal, necessitates monitoring for pulmonary symptoms. Hypertension must be controlled prior to initiation and monitored regularly. 

QT interval prolongation risk requires baseline and periodic ECGs and electrolyte assessments, especially with interacting drugs. Other critical precautions include the risk of hemorrhagic events, hypersensitivity reactions (managed with corticosteroids and dose adjustments), tumor lysis syndrome, impaired wound healing (withhold before/after surgery), hypothyroidism (monitor thyroid function), and potential embryo-fetal toxicity (advise on contraception). In pediatric patients, Slipped Capital Femoral Epiphysis (SCFE/SUFE) has been reported and requires monitoring.